Table 3.

Ongoing clinical studies of the MenABCWY vaccine

ClinicalTrials.gov identifier	Phase	Status	Details
NCT03135834	3	Recruiting	1590 participants (estimated)
			10 − 25 years of age
			To assess the immunogenicity and safety of MenABCWY in MenACWY vaccine-naive healthy adolescents and young adults
			To assess persistence of MenABCWY
			To assess immunogenicity and safety after MenABCWY booster
NCT04440163	3	Recruiting	2413 participants (estimated)
			10 − 25 years of age
			To assess the immunogenicity and safety of MenABCWY versus MenB-FHbp and MenACWY-CRM in both MenACWY vaccine-naive and -experienced healthy adolescents and young adults
NCT04645966	2	Recruiting	1325 participants (estimated)
			2 − 6 months of age
			To assess the immunogenicity and safety of MenABCWY administered on a 2 + 1 schedule in healthy infants
NCT04440176	2	Recruiting	300 participants (estimated)
			11 − 14 years of age
			To assess the safety and immunogenicity of MenABCWY administered at either months 0 and 12 or months 0 and 36

Data are from ClinicalTrials.gov and are current as of July 27, 2021. Another MenABCWY vaccine is in development, but this review is focused on a pentavalent vaccine that is constituted from 2 licensed meningococcal vaccines (MenB-FHbp and MenACWY-TT)